Clinical Trial Update: Post-marketing Safety Study of GlaxoSmithKline (GSK) Biologicals' Synflorix™ Vaccine, in Healthy Infants and Children in Sri Lanka

View source ↗

Summary

A post-marketing safety study of GlaxoSmithKline's Synflorix pneumococcal vaccine in healthy infants and children in Sri Lanka has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Synflorix (10-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Immunisation Against Streptococcus Pneumoniae | Status: WITHDRAWN